Bolt Biotherapeutics Stock Forum

$Bolt Biotherapeutics (BOLT.US)$
Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting
Bolt Biotherapeutics (BOLT) presented updated preclinical data for BDC-4182, their next-generation Boltbody™ ISAC targeting claudin 18.2, and findings from Phase 1 dose-escalation trial of BDC-1001 at SITC. BDC-4182 showed superior efficacy compared to claudin 18.2 ADCs in preclinical studies, demonstr...

$Bolt Biotherapeutics (BOLT.US)$ MT Newswires· 2 mins ago
Bolt Biotherapeutics (BOLT) shares were nearly 32% lower in premarket activity Wednesday following the company's announcement late Tuesday that it will stop the development of trastuzumab imbotolimod, BDC-1001, and has trimmed its workforce by about 50%.
The company said the BDC-1001 program is not expected to meet its pre-defined success criteria and it will now focus on developing its other cancer pipeline, which includes a first-in...

$Bolt Biotherapeutics (BOLT.US)$ Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu® 2 MINUTES AGO, 7:00 AM EST VIA GLOBENEWSWIRE

$Bolt Biotherapeutics (BOLT.US)$ Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.50) by 14 percent. This is a 25.86 percent increase over losses of $(0.58) per share from the same period last year. The company reported quarterly sales of $2.53 million which beat the analyst consensus estimate of $1.72 million by 46.98 percent. This is a 19.70 percent increase over sales of $2.11 million the same perio...

$Bolt Biotherapeutics (BOLT.US)$ Bolt Biotherapeutics to Present New Clinical Data from Completed Phase 1/2 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Solid Tumors at the ESMO Congress 2023

$Bolt Biotherapeutics (BOLT.US)$ Bolt Biotherapeutics Receives Orphan Drug Designation for BDC-1001 for Treatment of Gastric Cancers

$Bolt Biotherapeutics (BOLT.US)$
It has healthy balance sheet (25% debt) and income, believe it's under value with $1 now...

Upgrades
• $Credicorp (BAP.US)$ : Citigroup Upgrades to Buy from Neutral - PT $161 (from $128)
• $Bank of New York Mellon (BK.US)$ : Citigroup Upgrades to Buy from Neutral
• $CommScope (COMM.US)$ : Credit Suisse Upgrades to Outperform from Neutral - PT $17 (from $11)
• $Domino's Pizza (DPZ.US)$ : UBS Upgrades to Buy from Neutral - PT $385 (from $430)
• $Gilead Sciences (GILD.US)$ : JPMorgan Upgrades to Overweight from Neutral - PT $80 (fr...

Gainers:
• $Clovis Oncology (CLVS.US)$ +40.6% (Rubraca significantly improves progression-free survival in first-line maintenance treatment in women with ovarian cancer regardless of their biomarker status in phase 3 athena-mono trial)
• $Dare Bioscience (DARE.US)$ +13.61% (Organon and Dar Bioscience have entered into an agreement whereby Organon will license global rights to XACIATO)
• $KULR Technology (KULR.US)$ +9.5% (secured a battery sa...